Clinical trial
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
NCT05617885
Study timeline
Study start (actual)2023-08-09Date precision: day
Registry last updated2026-06-16
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Metastatic Prostate Cancerunresolved
Non-metastatic Prostate Cancerunresolved
Prostate Cancerunresolved
Interventions
DarolutamideDRUG · verified · RxNorm: darolutamide
AbemaciclibDRUG · verified · RxNorm: abemaciclib
GNRH-A GoserelinDRUG
DegarelixDRUG · verified · RxNorm: degarelix
Sponsors & collaborators
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05617885 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.